3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Lung Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Trauma, Nervous System
1
Thoracic Injuries
1
Stomach Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Radiculopathy
1
Pneumonia
1
Pathologic Complete Response
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma
1
Lung Diseases, Interstitial
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, B-Cell
1
Leukemia
1
Laryngeal Neoplasms
1
Klippel-Feil Syndrome
1
Interventions
ofatumumab
10
ibrutinib
6
Rituximab
5
acalabrutinib
4
Cyclophosphamide
3
spebrutinib
2
pirtobrutinib
2
obinutuzumab
2
navitoclax
2
fludarabine phosphate
2
Tablets
2
Lenalidomide
2
KW-2478
2
Chlorambucil
2
Antigens, CD19
2
ARQ531
2
venetoclax
1
tirabrutinib
1
pomalidomide
1
pivalyloxymethyl butyrate
1
immunotoxin HA22
1
idelalisib
1
idecabtagene vicleucel
1
fludarabine
1
dinaciclib
1
bempegaldesleukin
1
Vincristine
1
Rabeprazole
1
Prednisone
1
Observation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, B-Cell
×
Observation
×
Clear all
NCT01039376
2019-07-30
PROLONG
Novartis
Phase 3
Terminated
480 enrolled
30 charts